Le Lézard
Classified in: Health
Subject: ATY

Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX


NEW YORK, April 2, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ventyx Biosciences, Inc. (NASDAQ: VTYX).

Shareholders who purchased shares of VTYX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/ventyx-biosciences-inc-loss-submission-form/?id=73654&from=4

CLASS PERIOD: October 21, 2021 to November 6, 2023

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) VTX958, the Company's lead clinical product candidate, was less effective in treating psoriasis than defendants had led investors to believe; (ii) as a result, VTX958's clinical and/or commercial prospects were overstated; (iii) accordingly, the Company had misrepresented its ability to develop and commercialize effective product candidates; (iv) Ventyx's business prospects following the initial public offering were thus inflated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: April 30, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/ventyx-biosciences-inc-loss-submission-form/?id=73654&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of VTYX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 30, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE Gross Law Firm


These press releases may also interest you

at 06:50
Kenvue Inc. ("Kenvue"), today announced financial results for the fiscal first quarter ended March 31, 2024. "We entered 2024 with clear strategic priorities to reach more consumers, reinvent our ways of working to invest more behind our brands,...

at 06:35
Sage Therapeutics, Inc. , a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor conferences in May: 2024 RBCCM Global Healthcare...

at 06:31
Delivered Adjusted Diluted Earnings Per Share Results Above Projection, Due Primarily to Timing of Infant Formula Shipments; Reaffirm 2024 Financial Outlook Advanced Augmenting and Strengthening of Infant Formula Facilities, Recovery of...

at 06:30
Canadabis Capital with Sub Stigma Grow, a leading Canadian cannabis company, is pleased to announce its strategic expansion into the European market through a significant distribution agreement. This marks a pivotal moment in Stigma Grows history,...

at 06:28
Perrigo Company plc , a leading provider of Consumer Self-Care Products, today announced that Svend Andersen, Executive Vice President and President, Consumer Self-Care International (CSCI), intends to retire from the Company in December of this...

at 06:20
Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced initial safety and tolerability data from its ongoing Phase 1/2 gene therapy...



News published on and distributed by: